EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis

Kenji Watanabe iD, Fumihito Hirai iD, Kiyonori Kobayashi iD, Ken Takeuchi iD, Shinsuke Kurosu iD, Katsutoshi Inagaki iD, Ken-Ichi Iwayama iD, Makoto Naganuma iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Kenji Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine for Inflammatory Bowel Disease, Toyama University Hospital, Toyama, Japan. Hauptthemen laut MEDLINE: Budesonide, Colitis, Ulcerative, Remission Induction, Drug Administration Schedule. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd, Kissei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Early treatment response of ulcerative colitis (UC) symptom resolution is desirable. This post hoc analysis evaluated efficacy outcomes, including endoscopic remission, by responder status and the influence of once‐daily (QD) versus twice‐daily (BID) budesonide foam dosing in patients with UC.

Methods

Data were pooled from phase 2 and phase 3 clinical trials of budesonide rectal foam QD or BID or placebo for up to 12 weeks. Outcomes were evaluated by treatment and budesonide administration regimen and by responder group: early (rectal bleeding subscore [RBS] 0 from Week 2 through Week 6), delayed (RBS 0 at Week 6), and nonresponder (RBS > 0 at Week 6).

Results

The main analysis set included 55 (QD) and 120 (BID) budesonide‐treated patients and 116 placebo‐treated patients. At Week 6, the trend in early response rate was significant among treatment groups (BID, 45.3%; QD, 32.1%; placebo, 12.8%; P < 0.0001). Among BID recipients, trends for complete endoscopic remission rate (Mayo endoscopic score [MES] = 0) and endoscopic remission rate (MES = 0 or 1) were significant among responder status groups (early responder, 67.4% and 95.4%, respectively; delayed responder, 48.1% and 85.2%; nonresponder, 24.0% and 64.0%; P < 0.001 for both). Regardless of the administration regimen, most early responders achieved endoscopic remission at Week 6. Among responder status groups, early responders' cumulative non‐relapse period was greatest ( P = 0.07).

Conclusion

A BID budesonide administration regimen is preferred to increase the probability of early response and, following endoscopic remission, a better prognosis after stopping treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BudesonideColitis, UlcerativeRemission InductionDrug Administration ScheduleHumansTreatment OutcomeMaleFemaleAdultMiddle AgedTime FactorsAdministration, RectalAnti-Inflammatory AgentsClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

budesonideendoscopyulcerative colitis

Substanzen

BudesonideAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Internal Medicine for Inflammatory Bowel Disease, Toyama University Hospital, Toyama, Japan.
  • Department of Gastroenterology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  • Research and Development Center for New Medical Frontiers, Kitasato University, Sagamihara, Japan.
  • Department of Gastroenterology and Hepatology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
  • EA Pharma Co., Ltd., Tokyo, Japan.
  • Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.

ORCID-Profile: Kenji Watanabe, Fumihito Hirai, Kiyonori Kobayashi, Ken Takeuchi, Shinsuke Kurosu, Katsutoshi Inagaki, Ken-Ichi Iwayama, Makoto Naganuma

Förderung

  • EA Pharma Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd
  • Kissei

Zitieren

APA

Watanabe, K., Hirai, F., Kobayashi, K., Takeuchi, K., Kurosu, S., Inagaki, K., Iwayama, K. I., & Naganuma, M. (2024). Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16692

Vancouver

Watanabe K, Hirai F, Kobayashi K, Takeuchi K, Kurosu S, Inagaki K, et al. Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16692

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Kenji and Hirai, Fumihito and Kobayashi, Kiyonori and Takeuchi, Ken and Kurosu, Shinsuke and Inagaki, Katsutoshi and Iwayama, Ken-Ichi and Naganuma, Makoto},
  title = {Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16692}
}
Kostenlos starten →